NCT04521686 2026-04-22
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Phase 1 Active not recruiting
Eli Lilly and Company
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Istituto Ortopedico Rizzoli
University of Iowa
Memorial Sloan Kettering Cancer Center
UNICANCER